SGMO - Earnings call transcript Q1 2021 | Sangamo Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Sangamo First Quarter 2021 Teleconference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. now today, hand Corporate Aron would to conference Communications. I speaker your Feingold, Instructions] like the to over [Operator Head of Please go ahead.

Aron Feingold

the this Officer. our sangamo.com, me website. in Cockroft, Mark On discuss Sangamo expectations expenses Officer; of executive advancing our from are thank data no to XXXX we us presentation section team, not but results Chief Sangamo's to including our include, of operating Slides financial discussed call website, release, and except Scientific are historical to with This can certain programs, for our and our information, Chief lines SEC, differ report leadership time ended this date, Chief and Business financial filings several this Executive our is Actual December clinical Development; update XX, can available press current Officer; and the and XXXX. Macrae, undertake law. which With Reconciliation what GAAP our and Fontenot, our cash call Officer; sufficiency under the are be regarding operating stated specifically our page. the facilities; statements to year afternoon, annual statements resources; that These are and expenses. Head discuss required on this Chief corporate fact. made plans clinical forward-looking on opening the and afternoon not Investors and our Rob The guidance; found duty call, of Form by may found from of uncertainties Media Presentations Good non-GAAP members as this are trials, that enrolling Medical materially today's measure Schott, Sandy Bettina statements and on we regarding today manufacturing are presenting McClung, as expectations. today. for on such limited and fiscal of for These other includes we statements you performance our today. to, be joining Jason new conducting statements forward-looking risks XX-K relating Events statements subject in our on

like call CEO, Macrae. over the to I'd Now turn our Sandy to

Sandy Macrae

Aron, you, everyone Thank on call. afternoon and the good to

clinical of on This quarter, our to as cell our submitted early disease. the cell to The treatment program. We the as for Designation Pfizer’s the continues a that collaborations we partner with our to interactions, observations pivotal morning, product gene lead their this sickle through and Designation III based Phase has This agency. BIVVXXX, FDA also the AFFINE have was on Sanofi, as Designation SARXXXXXX, Orphan with the now regulatory fully investigators. highlighting continued announced With clinical received Orphan enrolled, our could for focus which from execution, registrational our clinical A on candidate hemophilia programs advancing Sanofi, granted CEO trial Track now therapy partners study Fast preliminary EMA lead-in and XXXX. known candidate, product therapy readout call, is announced we for progress earnings the Pfizer and lead

CAR-Treg candidates our progress candidate to by with as We pleased therapy in in STEADFAST therapies in are and sites rejection, to clinical initial the wholly-owned of therapy. a which clinical see transplant we our expected XXXX. we meeting cell autoimmune open to this first for CAR-Treg our and our will renal have the hope believe pleased In develop first-in-human at this step towards data pipeline. R&D study hope diseases, product the clinical sooner allogeneic were initiated than the as study a CAR-Treg which journey of end wholly-owned product expect we first We end present by patient medical our to year. March, study We the TXXXX, be of evaluating enrolled

Our research highly engine has been productive this quarter.

continue technology highlighted autoimmune of transcriptional address and innovative from programs. system proteins and to disease diseases. with our data zinc neurological The quarter finger focus versatility including areas, diseases our and zinc for the nervous to regulation We CAR-Tregs in for of central with our finger tau- challenging presentations this alpha-synuclein was publications

details strong of remote execute us. calls accomplishments. a call over have on am the conditions distancing the to the I team challenging to turn we to into we the our With to as team’s place as I team, resilience have quarter continued take proud of I kitchens adapted and marked Zoom the to Before colleagues Rob the impressed the that be to of moment and Rob? I our in like have employees of on clinical lab provide bedrooms. Sangamo to determination will ahead to catalyst-rich pandemic. additional one-year I'd from tune turn of our working our this acknowledge so year call by Development over and Head the in that, Schott, procedures

Robert Schott

afternoon. Good

Our with this and execution progress. are organization we remains focused quarter’s pleased development on in clinic, the

fourth characteristics XXXX in AFFINE readout to patients with a this two-year A dosing data Alta update expects giroctocogene of complete. prior enrollment As III study is quarter from pivotal a Factor hemophilia well trial. prophylaxis our as as The replacement collect Phase fitelparvovec minimum of purpose months of product the therapy hemophilia Pfizer's in the early study Pfizer six with A Sandy a to trial data the candidate as efficacy mentioned, VIII as in Phase study current year. lead-in in to of prospective AFFINE establish in evaluating of the baseline is this I/II

Products from product program, that I/II now of our EMA’s EMA patients granted STAAR weeks, in to In with Committee for the follow-up, of the plan had the from of recently determined relevant may hydroxyurea. Fabry versus enrolled clinical fourth received Track that on mature the long-term which progress a effects data candidate preliminary PRECIZN-X continue Medicinal well for days early study study, this partnered data the advantage advance clinically on as in disease find Designation as the will Phase than patient. reflect program month, Sanofi. initial year. cell we Sanofi three dataset This quarter the the we this early of that recently Designation data present to treated based announced treatment to present to have sickle Sanofi XX meeting and and was March, initial our XX that more Regarding Orphan XX with this and the comprehensive We FDA. Fast published a EMA. from expect shared potential SARXXXXXX, need We a medical We fourth obviate the this the encouraging. program observations, Orphan frequent study this end as year, by In BIVVXXX, more minutes, decision and the a known data suggest from respectively. the weeks, part Last the at

part oncology recent our the made this Kite to collaboration, Regarding review, not submit a their portfolio KITE-XXX as decision of at time. IND

for Kite We to are working closely determine the KITE-XXX. path with forward

finger and believe collaboration the cell developing space. best-in-class paired focused Sangamo’s the that positions platform within remains zinc and experience oncology Together, we therapies. development engineering engineered cell on well collaboration Kite’s expertise with capabilities oncology Our

HLA-AX expected. very CAR-Treg Patient now clinical receiving the candidates our TXXXX. mismatched is The Belgium kidney cell to the at autologous of pleased primary open living initiated sites tolerability from a and is we This donor. is patients evaluating study have an in HLA-AX and I/II earlier our Lastly, are product therapy assess than Netherlands. in to objective TXXXX, recruitment study safety Phase STEADFAST

graft rejection, rejection of the Secondary graft objectives and CAR-Treg acute include the cells incidents biopsy-confirmed in kidney. of of of the TXXXX localization incidents chronic transplant

be patients associated which side increased immunosuppressive effects, other to risk such We patients control plan as three up with infections to reduce group. six the group cells serious Safety surgery. the by option will Committee, The be to will each enroll patients was TXXXX go to conditions. expansion monitored cohort to their also the and a Patients undergo to the in plan with independent an plan dose up can the dose in We to doses an in evaluate to receiving collect of prior six in three ability give to group blood up leukapheresis a transplant patients. We to moving Monitoring before with study cohort. additional for evaluate ahead white TXXXX will or next systemic therapy, its XX cohort an which

of of the patient transplant will Treg antigen allow subset surgery and protein one-time period, We a a donated of isolate months recovery the present receptor, After infusion. and recognition the add specific to will individualized a cells CAR their on them several the or receive chimeric kidney. HLA-AX TXXXX cells to modify

and for immunosuppression. way year thereafter. the antigen CAR-Treg that as over dosing now understand biology additional the to has rejection Officer, demonstrate potential will expect enroll CAR-Treg programs. to of this process Treg to call to in study on our the humans, occur as in to is expect end details Scientific directing proof-of-concept reduce the of Jason? several Jason Fontenot I We We the TXXXX this by important Chief systemic transplanted an graft opportunity patient see this for We need study offering receptor, the the and will mitigate first believe organ by by cells chimeric months that turn research better to well these development. the

Jason Fontenot

of I sequence Today, few to ZFP any give our and precisely genome. exciting We Rob, engineer essentially research target an good you, am to can of finger in Thank the our you overview everyone. programs. delighted proteins or zinc afternoon, DNA

DNA ex We code. [indiscernible]. functional genetic interactions create tools targeting have have are range and potential methods diseases. include ZFP in DNA can without the to These expression editors and functional that targeted invented ZFP to with capability two modulate therapies we optimize and the We to treat and can of can methods we transcriptional activators gene to repressors specificity advancing vivo a with base vivo and altering that to domains. pair or developed domains with significant edit deploy powerful precision, Nucleases sequences this these

of Sandy factors system data are some exciting for and finger protein zinc preclinical on, develop had using central our As this nervous we to therapies quarter. highlights promising transcription touched diseases the

First, XX% this out the RNA selectively by transcriptional in repressors reduced program with tau administration, by without a Biogen AAV messenger in XX-month, Science data effects. from off-target our to published single delivered protein showed collaboration zinc XX% to detectable and tau-targeted tau Advances finger

preclinical for from that data program, the programs with significantly program the could Meeting data Annual tolerated Therapy alpha-synuclein-targeted our other you transcriptional from American Parkinson’s vivo. to next which as well Alzheimer’s week. Disease as alpha-synuclein finger human selected our Second, our presentation repressors Conference well at was look CXORFXX repress zinc And alpha-synuclein and Biogen finally, Pfizer, in were and also keeping presented as alpha-synuclein and Society to exclusively collaboration in Cell on have We Gene licensed forward advance. program, at we these been updated of and showed

to particular antigen in have activity. want to mentioned, excessive potential Regulatory treat which by or potent have Rob properties opens have our be this Tregs our to I additional of research mix STEADFAST polyclonal our As not and a Tregs, CAR-Treg unwanted enrollment on been study CAR-Treg and to color be some Unmodified provide studied characterized strategy natural for diseases therapeutically a overall portfolio. with diseases clinical called do regards autoimmune Treg, been immune to shown safe. immunosuppressive the harness cells T have quarter. target

tissue, be Tregs the developing to overcome expanded the the targeted target [indiscernible] The the to polyclonal localized to are believe and they the can disease with our that by approach may activated be CAR-Treg disease the by CAR-Treg Tregs antigen limitation our ideology will antigen. disease relevant simply in be linked is antigen and upon tissue. targeted or directing where We

IL-XXR, disease And oligodendrocyte are ongoing is in For GTS, reaction which to the is MOG sclerosis of expand the our target the Both a as the MOG they we or MS. we specific aim could inflammation be program, target targeting bowel suppress example, specifically involved MOG. site known programs similarly our our for in IBD antigens. to IL-XX in nervous to the multiple immune at pathology. sites central In system. at receptor or expressed program, gut interleukin to inflammation, drive the expressed in were investigating glycoprotein are will myelin of IBD CAR-Tregs for or we to inflammatory programming responsible CAR-Tregs pathogenic multiple where

produce genome engineering our develop from Tregs, finger vivo We are allogeneic to donors zinc platform cell Tregs using therapy. edited healthy CAR-Treg to ex off-the-shelf

of also are induced quantities We use iPSC potential renewable source Treg investigating cells. as pluripotent cells stem the of a or of large

obtaining financial due call proof-of-concept vivo. forward and to efficient these structures, in We presenting to preclinical turn now then data and developing our the We overview both of data, in are programs, Mark? vitro an preclinical results. making course. I the working for Mark progress and proprietary first to on will look on CAR over in

Mark McClung

everyone. you, Thank Jason, and good afternoon,

Aron on our financial quarter this available had As previously, found press can our for release are be results afternoon, this issued in website. mentioned the which

and equivalents our We candidates. the potential This reach R&D capabilities. clinical cash to our strong quarter, with $XXX will our of million We of programs, we quarter manufacturing marketable remains securities. invested moving important A in that BLA to and hemophilia submission our us approximately pipeline in sheet for believe product the the and preclinical advancement research balance in-house milestones, several build the including cash, our continuing ended allow forward

we our provided Turning to full-year call. guidance. like XXXX guidance would reiterate the prior in We to

which of stock-based exclude Sandy million $XX to million non-cash I'll operating be remarks. in for $XXX We year. estimated closing approximately of to million expenses continue it for approximately $XXX to now expect turn the expense to compensation back the non-GAAP range

Sandy Macrae

Thank like strength saying I'd to have you, are sheet on believe balance R&D with execute pleased development and to to this our Mark. quarter our organizations, milestones. the we across conclude research continue that and progress we the by

update Our manufacturing forward expect the readouts and initial for end please manufacturing Operator, year-end, operational cell to cell of year. look advance sickle and as catalysts to by a open milestones line be Fabry questions. therapy continues We key A. team which the hemophilia as our in-house well on by facilities, including the to data in two-year we

Operator

you. Thank the RBC. first Issi Instructions] line Luca from question [Operator from comes of Our

line now is Your open.

Lisa Walter

Perfect. Lisa Luca This is question. RBC. for Thanks from the taking on for

able need care head-to-head a of longer Just trial approval III though be an Fabrazyme. no pathway standard wanted run saw accelerated we may pursue to to they that ask will yesterday Fabry disease to for AvroBio versus Phase that

Thank that to news, how therapy was So your and just reaction wondering you. your for what gene that strategy product? forward your development does influence going

Sandy Macrae

time Thank has you agency. company in discussion some been individual you've What your Each was that now. with working the for their your question. on announcement? for Bettina, take Fabry

Bettina Cockroft

enrolling to currently enroll of Phase and Yes, fourth three soon. what have first ahead to thank that Sandy, mentioned, who are sure. enrolled is as Well, study And doing on we the full STAAR on quarter dose you I/II we focusing pressing all, the patients hope patient you. we Fabry heard, we're Rob study. those with have hope and

data We are in readout initial looking to forward QX. sharing

regulatory time. Now our currently will includes and data, recent collecting mentioned the sure, that And an study share updates biopsies appreciate front. agency. this design biomarker with the as point, will And too you the for we that unaffected kidney conduct we've in it's study it, is we on the engaging appropriate you're as to past by as at The well, early update are that referencing. at

Sandy Macrae

Bettina. you, Thank

Lisa Walter

taking for Thanks Great. the questions.

Operator

Thank you.

Raycroft Our from of question Maury line the from Jefferies. next comes

Your line is now open.

Unidentified Analyst

[indiscernible] This Raycroft. Hi. is for on Maury

XQ press half compared initiated done the patient For XXXX? to enrollment second the before noticed release, in earlier of needs to a be trial the Thanks. what we bit the TXXXX, work

Sandy Macrae

question. managing your sites. to Yes, the clinical pleased initiate group for we you with Thank were operations

now think with COVID. I time a a that dosing done have and for patients and of time simply CAR-Treg. of dosed remarkable the first they've patients This of the the it's moving patient. the in is job we forward preparing matter enrolling And the

manufacturing to conditions. prudent, area excitement be forward And going make matches to into many allow well. to – the sure to to the able sure And right take and care, is so process that have patient move autoimmune around and potential do we're us this drive CAR-Tregs right everyone's hopefully this we be

Unidentified Analyst

you. Thank

Operator

Thank you.

America. from Our question Meacham from comes of Geoff Bank the of line next

now is line open. Your

Aspen Mori

on Aspen the It’s questions. for guys. Geoff. for Thanks taking Hey

ones us. quick two from Just

regulatory hear more just CBER. Kite’s you a looking sort of I'd any to First decision to the agency the are from your of to Any thoughts mentality with on on reduced for sort the Sandy, all, not love bit current secondly, then specifically feeling And or shift in with submit of little environment, respect the respect? clarity IND. any communication

Thanks. if with you Just wanted additional share can feedback to you us. see any had

Sandy Macrae

philosophical pass award I one it medicines on discussion appropriate. take more to feels saw me Kite. business Peter and was then that given let for service his around for Mark this the an the and advancing to I'll week So Marks totally it

in is are is and great would your excitement extremely wonderful and that we is with good, other is some reality. good, about manufacturing self the process of good, often manufacturing job medicine seven difficult And reflect has its and We is science a hasn't [assignable]. stages want on have Mark, are got is what around, It's We clinical Mark talk a have meeting seriously ensuring gene We therapy trial are you excited it's about asking the meeting the changed relationship not they is it your CBER. and and Gilead. I'll a opinion. we're that – all the more? reality surprising the comfortable approved. doing these Kite, by take or confident to what thoughtful. agency regulatory invest good, that takes regulatory I But and I are to the They asked know the environment concept of for interactions is now flexible that? the greatly CMC and way get your harder pass to do now so

Mark McClung

submit made This of the to look mean, going potential is closer their from really Kite context something I the decision has a competitors hand little data products. two allow the product, in early this the not alternative IND of which Sure. context data and would drive that XXX bit emerging is with also were And team for be of program. made reiterated, would to time. startup these forward. an best-in-class ahead to But to expansion focus XXX the which has of been at utilization that understand the as Rob the a of on the the in Kite path the

to and oncology And to to finger platform develop so with Kite capabilities is therapies. best-in-class zinc really the apply development expertise advanced continue cell look opportunities paired of our in oncology engineering engineered goal cell to an the for

Aspen Mori

guys. Thanks,

Operator

you. Thank

line next Zhu Fargo Our from Yanan Wells the from comes of question Securities.

now is line open. Your

Yanan Zhu

Europe terms that TXXXX. have there Thanks enrolling for of is some And plan Belgium my any regarding procedure, difference, the see U.S.? you an relevant if and renal between the would I wondering, the for taking immunosuppression IND in how difference it's open a the in transplant procedure to question is I’m Netherlands. there for a that and in application? more Hi. treatment also Thanks. the questions. U.S. I to difference is have used U.S. any

Sandy Macrae

Thank you from a about how country-to-country. question differs it renal treat is question. you – interesting Bettina, because an That's would comfortable your you for to little feel transplant talk it? and

Bettina Cockroft

said in that I from for Yes, addressing transplant. differences are sure. there immunosuppression renal you Sandy, and mean, country-to-country

are – as the initiated are mentioned recently first in we've has two study We and countries. enrolling we

and the Netherlands European especially open do to also We other Belgium. countries. the study intend in mentioned countries, other in You've

something able is future. we update to be will hopefully that this So you in the

Robert Schott

the Schott. differences institutions I in respect might consequent immunosuppression therapy therapies immunosuppressive is even the we Rob add. following investigator on within find to And institution-to-institution between investigators. also can you is often therapy. This TXXXX differences judgment and with rely There and

Yanan Zhu

using transcription a factor versus you. advantages therapy to Could Thank potential using knock zinc gene? talk on target that gene delivers about finger And you follow-up a for protein program. a maybe That's it. very the for Got CXORFXX the shRNA, helpful. then down example, the

Sandy Macrae

help us Jason, Sure. be you with happy to. We'd one? that can

Jason Fontenot

Sure, Sandy.

platform our about and of key about target. finger think tune designated really fine proteins our is the interaction difference ability I with our to zinc technology the the platform the technology,

any difference control do and have to that out the with to can competitors. think between and we over our what I that, the identify that we ability accomplish there's ability a very And have to proteins therapy zinc we protein not So a fine zinc major finger have finger set with accomplish and off-target.

Sandy Macrae

These be expression then given therapies beyond of give a of it view, effect. would clinical promise our to the we the transcription point to Until hope seems promise. done to sure. humans, into will we know patients, our will will do frequently. And are is for need and factor, And get gives from if with lasting we that transcription we can and the although therapy factor important. really But long episomal fulfill that to once in a It seem dreadful that address animals. mission and we diseases, RNA them

Yanan Zhu

Great. the color. Thanks for

Operator

you. Thank

of the question next Gena Barclays. Our comes Wang from from line

Your now is open. line

Unidentified Analyst

is for questions. This Gena. [indiscernible] our Hi. taking on Thanks for

it update? like GbX I kidney patients could are require is reduction would you approval eGFR Fabry focused serve FDA defect? a grant in recruiting full the to surrogate Since monitor a think that like to do Thanks. based had endpoint, kidney on So biopsies predominantly assume safe as looks question. longer-term on And follow-up it to a you Fabrazyme with

Sandy Macrae

your Fabry in The have best the the now. for a long-term tractable. benefit for reduction important you GbX to its I And effect approval. is forward kidney on with the that to Thank question. kidney in very agency they pathway pathway make is to have eGFR therefore, a commitment think is is said mind the understanding What the clear my doing and

and study. on patients are are replacement pseudo naive enzyme are the We current are in recruiting therapy naive and that

We will kidney effect towards to are looking move then show we a biopsies. doing and biochemical

simply what literature of is population and renal damage think show tells had to is undamaged. on. the I of who that that an wide me very the the important patients patient my those from So early ranging already consequence reading from the renal And this is a patients damage are patients

results the that sensible work population the that the already But let's amongst in consequences. year wait, recruiting, renal with and let's path forward. we're let's will of at end be there So see patients

Unidentified Analyst

questions. Okay. taking our Thanks for

Operator

Thank you.

Cowen. of Our Baral line Ritu next question comes from from the

now line open. is Your

Ritu Baral

XX about XX% transplanted are of organs unique. afternoon, the to note ask the questions. – Good HLA-AX of HLA-AX. mismatched. you renally your Thanks corporate for rationale transplanted taking On actually deck, Slide to you that wanted for It's guys. XX% I the picking

that I Was and to XX% today all, comments general? that to wanted not are you make renal? second, implying sure seems auxiliary organs of your that of well. And thinking I also kidneys represent it like the renal target was proportion just of organs might were you as had targets program IBD, for were you wondering, that XX% in auxiliary had was transplant that in what First per picked sort multiple targets. between MS if an and

Sandy Macrae

on I'm the So Jason to getting is that this that we speak fundamental recruited strategy there of you But ask did an is mismatches. renal going do the to Jason population some activated on GPS who for because HLA-AX be Tregs. someone want means work to about to about That's that to its transplant – system. mismatch Tregs? general that HLA-AX are find the a XX% for mismatches can Jason, this taken the of beauty and of transplant. substantial And But the talk CAR-Treg patients kidney [indiscernible], other by to our the

Jason Fontenot

in about is one I Sure. first the this to think Yes. The Sangamo Thanks, really that effort. is mind to engineered I talking pioneering keep in opportunity we're humans. mean, things test is Sandy. the CAR-Tregs that of critical that's work really,

on only opportunity elegant of way mismatch design a the by just presented the And tissue very know transplanted virtue because targeting molecule we use AX the approach will the kidney be of present of the trial. that so AX kind the the to to

the for regards we highlighted And the The of platform, approach. targets connected etiology, one subject problems I to real disease the specific CAR versus cancer pick. a we just we’re in really CAR-T AX I So targets. But are targeting we of the that think that the antigens about some field the the to that's able that's become question, especially the of are oncology, real things pick that your see to for which the unique advantage challenge. to that tissue the that reason targets a has simply is in CAR-Treg are or as is us and identifying using exciting real

knowledge something where pathology able find that the connected we we’re that's that a to. future program amount simply an intend we targets either refining, something the the And in pick is and to localize advancing to and so use want of as gaining that knowledge disease by we for build which And TXXXX is huge upon in the we're tissue Tregs expressed to understanding or programs. to antigen

targets these why by we're in of keeping advancing limitations. each multiple And to pivot different that's opportunity targets the a so to

Ritu Baral

Got STEADFAST just it. study secondary end and question, on a therapy. the ability that a follow-up two have And following as think especially to up about the Slide that the on quick and immunosuppressive reduce you we XX, on previous points

signals vary rejection between this that And is reason I bullets? two the guess, of will first assumption to efficacy be first part Given parent move. my the correct as it's might to in that – the the could of regimens, graft those acute can therapy generate a the from I'm needle Is that center this assumption? Or especially? immunosuppressive quantify center. reductions How we asking protocol, the

Sandy Macrae

to of The advantage lose which health by their with care normal immunosuppression, that is standard of a modern The comes edge medicine study is allow is the investigators. has kidney. of with that kinds rarely way they cutting patients avoid This state-of-the-art consequences. all

everyone not love would progress the would that. we without to course, But the do Of study thing. same

program. when And from so Tregs. to we reduced part do about they will watch this, renal happens that We'll use the next what And understand they this immunosuppression. what the – the their information of gather gather we'll when the and design study biopsies. next we'll from We'll information

Ritu Baral

it. the questions. taking Got for Thanks

Operator

you. Thank

Ben line the comes Stifel. question Burnett from next Our from of

is now Your line open.

Unidentified Analyst

This on Hi. Burnett. [Kelly Thanks for Burris] is for Ben taking our questions.

first to provide any if any if Just expect you doses additional could color had just see was you that provide one And may the you one I could color other about data. on at it? quick look TXXXX. wondering about at starting the

Sandy Macrae

three to will now. doses, and do haven't We be some be that said the some we're going will about number know it later, up haven't of we cells talked to we doses, will – anything about which I talk but

Unidentified Analyst

Okay. questions. our for Thanks Awesome. taking

Operator

you. Thank

from line of question from Andreas Our Securities. comes Argyrides next Wedbush the

line now Your is open.

Andreas Argyrides

question. a candidate assets our we library This is the Good from afternoon, selected Moussatos. the to Thanks. And respective for regard the these for you With Andreas see the clinic? abstracts, have enter partners yet Liana taking when might lead and thank ASGCT on generated?

Sandy Macrae

programs, with For about on closely partner them. I with worked our stem steering We them. to to partners them. talk committees sit We

And it's the to for of relationship so rules talk it. – but is about the them

Andreas Argyrides

Okay.

investors from we should the at standpoint? how presented So scientific look being or abstracts a

Sandy Macrae

progress From speaking I future. we – And forward of a look fair. are assure the about excited think the them CNS and more in that to want scientific to very but you by partners our standpoint, is I the assets,

Andreas Argyrides

Thank you. Okay. appreciate I it.

Operator

you. Thank

Our question next Guggenheim Debjit from line Chattopadhyay the of from Securities. comes

open. Your now line is

Boran Wang

guys. Thanks on Debjit. question. for taking This for Hi, is my Evan

So from trials or the be and Fabry entry verticillata, acroparesthesia noticed must hidrosis have angiokeratomas that included. to patients we clinical cornea the

you can percentage Fabry estimate symptoms? those of of the symptoms those any patients and with why us tell particular So

Sandy Macrae

So Bettina, this feels you. like one for

Bettina Cockroft

Sandy. Yes. you, Thank

who documented to for are you These out enrolled of acroparesthesia more, symptoms trials.gov, have rightly if Fabry symptoms, ensure are the need to hidrosis, to at as are have and patients – we STAAR of are Fabry be point classic and we that those And the to diagnosis listed patients verticillata, not have least Fabry this condition. the clinical cornea study. angiokeratomas. you be criteria beyond so disease, that enrolling patients. into is one the that our So able of underlying do and They exclusion listed, inclusion study symptoms

Boran Wang

you. Great. Okay. Thank

Operator

I'm remarks. back turn Sandy over for closing like no time, to further showing to you. At I questions. call Macrae, CEO the this Thank would

Aron Feingold

take I'll you much. so Thank is This that. Aron.

on to So joining everyone future a once your and thanks Have look for questions. forward afternoon. us updated keeping development. We great today again our you for

Operator

participating. for This Thanks conference today's call. concludes

You may disconnect. now

Sangamo Therapeutics (SGMO) 5 May 212021 Q1 Earnings call transcript